Tag:
Sanofi-Aventis
Latest Headlines
Latest Headlines
Stem cells step forward in ALS
A consortium of researchers from across the U.S. has taken a step forward in the treatment of amyotrophic lateral sclerosis by transplanting neural stem cells into mice and slowing the paralysis caused by this lethal and incurable neurodegenerative disease.
Mold may lead to Sanofi cancer drug shortage
Problems with mold at a Sanofi ($SNY) plant that flooded last fall has forced the plant to close for remediation, setting the stage for a global shortage of the bladder cancer drug ImmuCyst.
Sanofi's Hexaxim vax gets EMA thumbs up
The European Medicines Agency (EMA) has adopted a positive opinion for Sanofi Pasteur's hexavalent vaccine for babies and toddlers, Hexaxim, as part of a procedure designed to evaluate medicinal products intended for markets outside the European Union.
Japan OKs Sanofi's inactivated polio vaccine
Japan has granted marketing approval for its first inactivated polio vaccine (IPV), Sanofi's Imovax Polio, and will begin using the vaccine in public immunization programs beginning Sept. 1.
Sanofi, BMS collect their $444M in Plavix damages
Apotex has finally paid its Plavix dues. The generics maker has handed over $444 million to Sanofi ($SNY) and Bristol-Myers Squibb ($BMY), as repayment for its premature launch of generic Plavix back...
Sanofi CEO: Look out below, profits are falling
It wasn't Sanofi's fourth-quarter profits, which grew by 13%. Nor was it the 8.8% increase in sales for the period, or the 5.3% increase in 2011 sales, to €33.39 billion ($44.3...
Is Sanofi destined to be 'small player' in MS?
Sanofi ($SNY) CEO Chris Viehbacher (photo) is talking up trial results on his multiple sclerosis hopeful Lemtrada, acquired in his buyout of Genzyme. But advances by other companies are making it
Sanofi, Novartis favor diagnostics partnerships over M&A
The initial speculation--or was it a wish?--that a Sanofi ($SNY) or Novartis ($NVS) might mount a counterbid to Roche's hostile $5.7 billion offer for Illumina was chilled rather effectively by a
Europe makes Sanofi chief thankful for emerging markets
Although Sanofi ($SNY) CEO Christopher Viehbacher (photo) sees a glimmer of light at the end of the long Eurozone tunnel, he's still glad the French drugmaker doesn't depend on Europe as much as it
Genzyme plant approval marks GMP comeback
The Genzyme unit of Sanofi ($SNY) announced today that it has won FDA approval for its new Framingham, MA, facility, the new production home of Fabry disease drug Fabrazyme. The plant won European...
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- …
- next ›
- last »
